{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-083280","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2024-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.108722+00:00","generated_at":"2026-05-31T15:41:26.700706+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Cognition Therapeutics files investor presentation on Phase 2 SHINE results for CT1812 Alzheimer's study","bullets":["Phase 2 proof-of-concept SHINE study of CT1812 in mild-to-moderate Alzheimer's disease.","Results presented on July 29, 2024 via investor presentation filed as exhibit.","No specific efficacy or safety endpoints disclosed in the 8-K filing text."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-083280","json":"https://secwatch.observer/filing/0001104659-24-083280.json","markdown":"https://secwatch.observer/filing/0001104659-24-083280.md","text":"https://secwatch.observer/filing/0001104659-24-083280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924083280/0001104659-24-083280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924083280/tm2420336d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:41:26.700706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}